|Day Low/High||332.40 / 350.92|
|52 Wk Low/High||58.81 / 464.00|
The New York Fed's August Survey of Consumer Expectations could be problematic.
Plus, Zscaler largely delivers for its owners with its latest results.
I could be wrong, but as far as I can tell, nobody else is telling the story about the sudden movement in these yields.
One cannot say that the financial marketplace is completely disrespecting or indifferent to what Fed Chair Powell may signal.
The fiscal football remains a greater threat this week than anything Fed Chair Jerome Powell says on Zoom this Friday.
Investors come into this week with 'all eyes' on the Kansas City Fed's economic symposium come week's end.
Watch Medigen stock, as the Taiwanese president becomes one of the first citizens of the island nation to roll up her sleeve.
A wall of liquidity seems to absorb every dip. But there are also enough reasons to be ever vigilant.
The negative economic impacts from the spread of the Delta variant of the SARS-CoV-2 virus are becoming apparent everywhere.
These guys are aware that the U.S. was energy independent less than a year and a half ago, right?
One thing we know is that the current wave of the pandemic just seems to be getting worse.
These picks are attractive for value-oriented dividend investors looking for strong current income potential.
The shares are only trading at 17 times forward earnings, and might not be fully valued just yet.
Doesn't the Fed now have to taper asset purchases simply to avoid becoming an even greater force in these markets?
Also, there's reason to turn J&J's one shot jab into a two shot vaccine just like the rest.
Plus, China's central bank plans to cut its Reserve Ratio Requirement and Wells Fargo looks to exit a business line.
Contrary to popular belief, this economic recovery that we seem to be enjoying has hit a pressure point.
There's a split growing at the FOMC as to just how transitory the current burst of consumer level inflation actually is.
CVAC is now working on a 'next generation' COVID-19 vaccine candidate with GlaxoSmithKline.
I prefer the bear put spread over the covered equity play due to the decreased risk to principal, despite the capped potential for profit.
How long have we cried out in the wilderness with no one listening? Finally, perhaps, a champion has risen from the depths.
Last year's top-performing stock market worldwide has been a disappointment since setting an all-time high in February. Could it have just turned?
We've been caught with our pants down, largely because we had no faith in the smartest people in the country.
The market seems to rejoice from the latest mask utterance out of the CDC, but the action at the Nasdaq should give traders pause.
ARCT's IP is incredibly valuable, and may in fact be invaluable.
The market came within whiskers of a technical breakdown on Thursday, yet few people seem to know or care.